Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“More Drugs, More Toxicity, but No Better Outcomes: Lessons From LITESPARK-012
Phase III / Advanced ccRCC / n=1,688. Adding belzutifan (HIF-2α) or quavonlimab (CTLA-4) to pembrolizumab + lenvatinib failed to improve PFS or OS.
Key results:
- mPFS: 20.8 / 20.7 vs 23.7 months
- PFS HR: 1.08 / 1.07
- OS HR: 1.04 / 1.12
- ORR: 69% / 69% vs 76%
The critical issue: AE-related treatment discontinuation increased to ~51% with triplet therapy vs 36% with the doublet.
A strong comparator, greater toxicity, and no demonstrated clinical benefit. Biological rationale does not guarantee clinical benefit. More treatment is not always better treatment.
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study – Annals of Oncology.”
Title: Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
Authors: Brian I. Rini, Toni K. Choueiri, Martin H. Voss, Mauricio Burotto, Jan Oldenburg, Howard P. Gurney, Thomas R. Ferguson, Hans Hammers, Laurence Albiges, Yüksel Ürün, Roberto I. Romero Diaz, Mustafa Özgüroğlu, Patricio Yañez Weber, Elena Verzoni, Camillo Porta, Alexandra Drakaki, Jun Guo, Nobuaki Matsubara, Aiying Chen, Joseph E. Burgents, Karla G. Rodriguez-Lopez, Thomas B. Powles
You can also read:
